{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:33:04Z","timestamp":1768451584287,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.msard.2022.104074","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T01:55:24Z","timestamp":1658800524000},"page":"104074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Archetypal analysis of visual fields in optic neuritis reveals functional biomarkers associated with outcome and treatment response"],"prefix":"10.1016","volume":"67","author":[{"given":"Elena","family":"Solli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiten","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Elze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis R.","family":"Pasquale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Branco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kupersmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2022.104074_bib0001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group","volume":"326","author":"Beck","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.msard.2022.104074_bib0002","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","article-title":"The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial","volume":"101","author":"Beck","year":"1994","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.msard.2022.104074_bib0003","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/archopht.1993.01090030018009","article-title":"Recovery from severe visual loss in optic neuritis","volume":"111","author":"Beck","year":"1993","journal-title":"Arch. Ophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2022.104074_bib0004","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1080\/02713683.2016.1205630","article-title":"Clinical correlates of computationally derived visual field defect archetypes in patients from a glaucoma clinic","volume":"42","author":"Cai","year":"2017","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.msard.2022.104074_bib0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/00401706.1994.10485840","article-title":"Archetypal analysis","volume":"36","author":"Cutler","year":"1994","journal-title":"Technometrics"},{"issue":"103","key":"10.1016\/j.msard.2022.104074_bib0006","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2014.1118","article-title":"Patterns of functional vision loss in glaucoma determined with archetypal analysis","volume":"12","author":"Elze","year":"2015","journal-title":"J. R. Soc. Interface"},{"issue":"8","key":"10.1016\/j.msard.2022.104074_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v030.i08","article-title":"From spider-man to hero - archetypal analysis in R","volume":"30","author":"Eugster","year":"2009","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.msard.2022.104074_bib0008","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0161-6420(00)00284-0","article-title":"Mapping the visual field to the optic disc in normal tension glaucoma eyes","volume":"107","author":"Garway-Heath","year":"2000","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.msard.2022.104074_bib0009","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archophthalmol.2010.16","article-title":"Visual field profile of optic neuritis a final follow-up report from the optic neuritis treatment trial from baseline through 15 years","volume":"128","author":"Keltner","year":"2010","journal-title":"Arch. Ophthalmol. Chic"},{"issue":"2","key":"10.1016\/j.msard.2022.104074_bib0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archopht.1993.01090020085029","article-title":"Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic neuritis study group","volume":"111","author":"Keltner","year":"1993","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.msard.2022.104074_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102400","article-title":"Promising recovery biomarkers after first event acute demyelinating optic neuritis","volume":"45","author":"Klineova","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104074_bib0012","first-page":"5414","article-title":"Scanning laser polarimetry, but not optical coherence tomography predicts permanent visual field loss in nonarteritic anterior ischemic optic neuropathy","volume":"54","author":"Kupersmith","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.msard.2022.104074_bib0013","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1212\/01.wnl.0000267272.60714.42","article-title":"Visual function at baseline and 1 month in acute optic neuritis - predictors of visual outcome","volume":"69","author":"Kupersmith","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2022.104074_bib0014","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.8.5.2","article-title":"Comparison of methods to detect and measure glaucomatous visual field progression","volume":"8","author":"Rabiolo","year":"2019","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.msard.2022.104074_bib0015","series-title":"Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","article-title":"Archetypal analysis of visual fields in optic neuritis reveals functional biomarkers associated with outcome and treatment response","author":"Solli","year":"2021"},{"issue":"1","key":"10.1016\/j.msard.2022.104074_bib0016","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ophtha.2010.04.038","article-title":"Interobserver agreement and intraobserver reproducibility of the subjective determination of glaucomatous visual field progression","volume":"118","author":"Tanna","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2022.104074_bib0017","doi-asserted-by":"crossref","DOI":"10.1109\/JTEHM.2020.2982150","article-title":"Convex representations using deep archetypal analysis for predicting glaucoma","volume":"8","author":"Thakur","year":"2020","journal-title":"IEEE J. Transl. Eng. Health Med."},{"issue":"6","key":"10.1016\/j.msard.2022.104074_bib0018","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bjo.87.6.726","article-title":"Interobserver agreement on visual field progression in glaucoma: a comparison of methods","volume":"87","author":"Viswanathan","year":"2003","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.msard.2022.104074_bib0019","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ophtha.2019.12.004","article-title":"Artificial intelligence classification of central visual field patterns in glaucoma","volume":"127","author":"Wang","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.msard.2022.104074_bib0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamaophthalmol.2019.5413","article-title":"Characterization of central visual field loss in end-stage glaucoma by unsupervised artificial intelligence","volume":"138","author":"Wang","year":"2020","journal-title":"JAMA Ophthalmol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482200582X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482200582X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:26Z","timestamp":1761901406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482200582X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":20,"alternative-id":["S221103482200582X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104074","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Archetypal analysis of visual fields in optic neuritis reveals functional biomarkers associated with outcome and treatment response","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104074"}}